Extraordinary General Meeting in Vigmed Holding AB (publ) resolves on a new share issue of approximately MSEK 57


On 12 November 2015, Vigmed Holding AB (publ) held an Extraordinary General
Meeting. At the EGM, 21,155,456 shares were represented corresponding to 48 % of
the total number of shares and votes in the company. The EGM resolved, in
accordance with the Board of Directors’ proposal, on a new share issue of not
more than 21,916,666 shares resulting in an increase of the share capital by not
more than approximately SEK 442,330.06. The company’s shareholders shall have
preferential right to subscribe for new shares in relation to their previous
shareholdings whereby two (2) shares shall entitle to subscription of one (1)
new share. The subscription price shall be SEK 2.60 per new share which means
that the rights issue, at full subscription, will provide the company with
proceeds of approximately MSEK 57 before rights issue costs.

The record date for entitlement to participate in the rights issue with pre
-emptive right is 19 November 2015. Subscription for new shares by exercise of
subscription rights shall be made by simultaneous cash payment during the period
as from 23 November 2015 up to and including 7 December 2015.

Helsingborg, November 12, 2015

Vigmed Holding AB (publ)
For further information contact:

Chairman of the board, Lennart Holm +46 70 630 8562 or CEO, Henrik Olsen +46 76
349 7364
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries and the associated risk of cross infections with blood
-borne infectious diseases by offering the market unique needle-protected
products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is
traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has
approximately 5 500 shareholders. Remium Nordic AB is the Company’s Certified
Advisor. Additional information about the company can be found on Vigmed’s
website: www.vigmed.com/investor

Attachments

11126069.pdf